These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 38133871)

  • 21. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
    Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
    J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
    Lin A; Zhang J; Luo P
    Front Immunol; 2020; 11():2039. PubMed ID: 32903444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterogeneity of MSI-H gastric cancer identifies a subtype with worse survival.
    Yang Y; Shi Z; Bai R; Hu W
    J Med Genet; 2021 Jan; 58(1):12-19. PubMed ID: 32170001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current treatment and recent progress in gastric cancer.
    Joshi SS; Badgwell BD
    CA Cancer J Clin; 2021 May; 71(3):264-279. PubMed ID: 33592120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of sintilimab-based regimens against advanced gastric and gastroesophageal junction adenocarcinoma.
    Wang Y; Zhao J; Yu H; Wang J; Zhang N; Cao B
    J Cancer Res Ther; 2021 Nov; 17(5):1234-1240. PubMed ID: 34850772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy-Based Neoadjuvant Treatment of Advanced Microsatellite Instability-High Gastric Cancer: A Case Series.
    Liu L; Woo Y; D'Apuzzo M; Melstrom L; Raoof M; Liang Y; Afkhami M; Hamilton SR; Chao J
    J Natl Compr Canc Netw; 2022 Aug; 20(8):857-865. PubMed ID: 35948034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action.
    Fornaro L; Lonardi S; Catanese S; Nappo F; Pietrantonio F; Pellino A; Angerilli V; Signorini F; Salani F; Murgioni S; Neculaescu IA; Bruno R; Vivaldi C; Ricagno G; Masi G; Bergamo F; Ugolini C; Fassan M
    Gastric Cancer; 2023 Nov; 26(6):958-968. PubMed ID: 37382783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
    Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.
    Greally M; Chou JF; Chatila WK; Margolis M; Capanu M; Hechtman JF; Tuvy Y; Kundra R; Daian F; Ladanyi M; Kelsen DP; Ilson DH; Berger MF; Tang LH; Solit DB; Diaz LA; Schultz N; Janjigian YY; Ku GY
    Clin Cancer Res; 2019 Oct; 25(20):6160-6169. PubMed ID: 31337644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salvage Treatment Using Anti-PD-1/CTLA-4 Immunotherapy After Failure of Neoadjuvant Chemotherapy in Microsatellite Instable Gastroesophageal Carcinoma.
    Klein O; Brown WA; Saxon S; Haydon A
    Oncologist; 2021 Jun; 26(6):461-464. PubMed ID: 33856094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic approaches to gastroesophageal junction adenocarcinomas.
    Blom RL; Bogush T; Brücher BL; Chang AC; Davydov M; Dudko E; Leong T; Polotsky B; Swanson PE; van Rossum PS; Ruurda JP; Sagaert X; Tjulandin S; Schraepen MC; Sosef MN; van Hillegersberg R
    Ann N Y Acad Sci; 2014 Sep; 1325():197-210. PubMed ID: 25266026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequent microsatellite instability in papillary and solid-type, poorly differentiated adenocarcinomas of the stomach.
    Arai T; Sakurai U; Sawabe M; Honma N; Aida J; Ushio Y; Kanazawa N; Kuroiwa K; Takubo K
    Gastric Cancer; 2013 Oct; 16(4):505-12. PubMed ID: 23274922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of immune checkpoint inhibitors and microsatellite instability in gastric cancer.
    Yan SY; Fan JG
    World J Gastroenterol; 2024 Jun; 30(21):2734-2739. PubMed ID: 38899328
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
    Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma.
    Hjortland GO; Meza-Zepeda LA; Beiske K; Ree AH; Tveito S; Hoifodt H; Bohler PJ; Hole KH; Myklebost O; Fodstad O; Smeland S; Hovig E
    BMC Cancer; 2011 Oct; 11():455. PubMed ID: 22014070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy Efficacy in the Initial Lines of Treatment in Advanced Upper Gastrointestinal Malignancies: A Systematic Review of the Literature.
    Kamposioras K; Ntellas P; Nikolaou M; Germetaki T; Gazouli I; Dadouli K; Zarkavelis G; Amylidi AL; Tolia M; Mauri D
    JNCI Cancer Spectr; 2021 Dec; 5(6):. PubMed ID: 34926989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma.
    Wang Z; Wang X; Xu Y; Li J; Zhang X; Peng Z; Hu Y; Zhao X; Dong K; Zhang B; Gao C; Zhao X; Chen H; Cai J; Bai Y; Sun Y; Shen L
    BMC Med; 2022 Apr; 20(1):133. PubMed ID: 35443723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer of the gastroesophageal junction: combined modality therapy.
    Ilson DH
    Surg Oncol Clin N Am; 2006 Oct; 15(4):803-24. PubMed ID: 17030275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma.
    Baxter MA; Spender LC; Cairns D; Walsh S; Oparka R; Porter RJ; Bray S; Skinner G; King S; Turbitt J; Collinson D; Miedzybrodzka ZH; Jellema G; Logan G; Kennedy RD; Turkington RC; McLean MH; Swinson D; Grabsch HI; Lord S; Seymour MJ; Hall PS; Petty RD
    ESMO Open; 2024 May; 9(5):103450. PubMed ID: 38744099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Defining the role of upfront immune checkpoint inhibition in advanced HER-2 negative gastric or gastroesophageal junction adenocarcinoma.
    Rogers JE; Ajani JA
    Ann Palliat Med; 2022 Jun; 11(6):2180-2183. PubMed ID: 35695051
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.